Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system

Herz
Lars MichelDaniel Finke

Abstract

Immune checkpoint inhibitor (ICI) therapy induces an immune response against cancer cells. Immune checkpoint inhibitor therapy has tremendously improved the prognosis for a large number of cancers, but is associated with considerable immune-related adverse events (irAEs). Cardiovascular complications from ICI therapy occur in a modest proportion of patients, but show the highest lethality rates of all ICI-related complications. While ICI-related myocarditis is the most dangerous complication, its clinical manifestation varies, e.g., asymptomatic reduction of left ventricular function, isolated increase in cardiac troponins, and arrhythmias. This review delineates current data on cardiovascular complications of ICI therapy. The effects of ICI therapy on the cardiovascular system are classified in the context of preclinical data on the biochemical and immunological function of the immune checkpoint signaling pathways in the heart and the vascular system. Incidence, suspected pathomechanisms, typical symptoms, as well as recommended diagnostics are summarized. Current therapy recommendations for ICI-related cardiotoxicity are outlined and innovative new approaches with high potential for improving outcome in ICI-related myocarditi...Continue Reading

References

Aug 8, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Julie A LucasVicki R Kelley
Feb 11, 2010·European Journal of Human Genetics : EJHG·Volker RuppertUNKNOWN German Heart Failure Network
Apr 23, 2010·International Immunology·Jian WangTaku Okazaki
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 12, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Margarite L TarrioAndrew H Lichtman
Jul 5, 2013·European Heart Journal·Alida L P CaforioUNKNOWN European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Jan 17, 2015·Circulation Research·Ulrich Hofmann, Stefan Frantz
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Apr 14, 2016·Proceedings of the National Academy of Sciences of the United States of America·Katrin KlockeKajsa Wing
Aug 18, 2016·Journal for Immunotherapy of Cancer·Lucie HeinzerlingJason J Luke
Nov 3, 2016·The New England Journal of Medicine·Douglas B JohnsonJavid J Moslehi
Feb 22, 2017·Current Cardiology Reports·Daniel Y WangJavid J Moslehi
Apr 13, 2017·Current Treatment Options in Cardiovascular Medicine·Varun JainAna Barac
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Sep 12, 2017·The New England Journal of Medicine·Jeffrey WeberUNKNOWN CheckMate 238 Collaborators
Oct 11, 2017·Nature Reviews. Immunology·Arlene H Sharpe, Kristen E Pauken
Nov 22, 2017·Journal for Immunotherapy of Cancer·Timothy G NorwoodRobert M Conry
Dec 26, 2017·The Canadian Journal of Cardiology·Mauro FrigeriPierre-Yves Dietrich
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Mar 15, 2018·Lancet·Javid J MoslehiDouglas B Johnson
Mar 24, 2018·Journal of the American College of Cardiology·Syed S MahmoodTomas G Neilan
Mar 24, 2018·Science·Antoni Ribas, Jedd D Wolchok
May 29, 2018·The Oncologist·Sarju Ganatra, Tomas G Neilan
Sep 8, 2018·The Lancet Oncology·Alexander R LyonJames Larkin
Sep 22, 2018·Lancet·Dirk SchadendorfSelma Ugurel
Nov 30, 2018·Nature Reviews. Drug Discovery·Jun TangYunqing Lin
Jan 5, 2019·European Journal of Medical Research·Lars Michel, Tienush Rassaf
Feb 1, 2019·Journal of Thoracic Disease·Lars MichelMatthias Totzeck
Feb 6, 2019·Cardiovascular Research·Nir GrabieRobert Padera
Feb 24, 2019·Journal for Immunotherapy of Cancer·Magid AwadallaTomas G Neilan
Mar 1, 2019·Clinical Pharmacokinetics·Maddalena CentanniJ G Coen van Hasselt
Jun 13, 2019·The New England Journal of Medicine·Khashayar EsfahaniWilson H Miller
Jun 13, 2019·The New England Journal of Medicine·Joe-Elie SalemMathieu Kerneis

❮ Previous
Next ❯

Citations

Sep 17, 2020·Cancer Chemotherapy and Pharmacology·Ludovic FournelMarco Alifano
Jan 29, 2022·MMW Fortschritte der Medizin·Lars Michel, Tienush Rassaf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.